GLOBALES: Hikma trims FY revenue forecast on Advair U.S. launch delay
 Inicio > Internacionales | Publicado el Viernes, 19 de Mayo del 2017
GLOBALES: Hikma trims FY revenue forecast on Advair U.S. launch delay
Noticias Relacionadas: HikmaRevenueForecastLaunchGeneric

Esta noticia ha sido leída 99 veces
GLOBALES: Hikma trims FY revenue forecast on Advair U.S. launch delay

Reuters / Drugmaker Hikma Pharmaceuticals Plc ( HIK.L ) on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.

Shares of the company fell as much 7.47 percent to 1,573 pence, the lowest since May, 2014. They were the top loser on the FTSE 100 bluechip index .FTSE and the pan-European Stoxx 600 index .

Hikma now expects full-year revenue to be in the range of $2.0 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion.

Earlier this month, the company said approval for its generic version of GlaxoSmithKline Plc's ( GSK.L ) blockbuster lung drug Advair was unlikely in 2017.

Hikma and its partner Vectura Group Plc ( VEC.L ) are in a race with Mylan ( MYL.O ) to launch the first U.S. generic copy of Advair. The FDA has already delayed approval of Mylan's ( MYL.O ) version.

Hikma on Friday lowered its 2017 revenue forecast for its generics business to $670 million, down from its earlier forecast of $800 million.

"This assumes we do not launch our generic version of Advair Diskus in 2017 and reflects the intensifying competitive environment in the U.S.," the company said in a statement.

Hikma maintained its full-year revenue estimate for its injectables unit at a range of $800 million-$825 million, with core operating margin seen in the high 30s.





(Reporting by Sanjeeban Sarkar and Tenzin Pema in Bengaluru; Editing by Sunil Nair)

GLOBALES: Hikma trims FY revenue forecast on Advair U.S. launch delay

Con Información de Reuters

http://entornointeligente.com/articulo/9996971/GLOBALES-Hikma-trims-FY-revenue-forecast-on-Advair-US-launch-delay-19052017

Síguenos en Twitter @entornoi

Para mas información visite: Mundinews.com


Última tecnología en grabado láser para acrílicos madera y MDF
http://artelaser21.com/







Otras noticias de interés
Destacadas

Niños guatemaltecos participan en torneo Iberoamericano de fútbol en Panamá
App móvil Mobijob representará a Colombia en el Mobile World Congress
20 ongs elevaron a la ONU petición de elecciones libres en Venezuela
Nestlé y UNIBE promueven un estilo de vida saludable
Especialistas de evaluación educativa de América Latina  preparan en la República Dominicana el primer piloto del  estudio regional ERCE
¡En Wingo, llegamos a nuestro primer millón de pasajeros!
Escuelas de perdón y reconciliación (ESPERE)
Una joya de feminidad y dulzura con Flowerbomb de Viktor & Rolf
Escuela Nacional de Cine formará a la próxima generación de realizadores cinematográficos del país
 Banesco aportó Bs. 7.14 millones a dos socios sociales gracias al reciclaje de papel
Placeres del fin del mundo
Expodigitur 2018: "Un escenario para que la tecnología potencie el turismo"




ATENCION: TODOS LOS CONTENIDOS PUBLICADOS EN ESTE SITE SON PROPIEDAD DE SUS RESPECTIVOS DUENOS, ENTORNOINTELIGENTE NO SE HACE RESPONSABLE POR LOS CONTENIDOS DE TERCEROS. CADA NOTICIA ESTA ASOCIADA AL MEDIO DE ORIGEN.
LOS AVISOS DE GOOGLE SON PROPIEDAD DE GOOGLE Y EN NINGUN MOMENTO GUARDAN RELACION CON LA LINEA EDITORIAL DEL PORTAL ENTORNOINTELIGENTE.COM